Applied DNA's Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies Against Three Variants

Applied DNA Sciences Inc APDN and its program development partner, Evvivax S.R.L., have announced results from an in vitro neutralization study of sera evaluating the company's COVID-19 vaccine in felines.
Data includes the trial cohort of 11 domestic felines vaccinated with the Applied DNA-Evvivax LinearDNA COVID-19 vaccine candidate against three COVID-19 variants.
Data showed that all vaccinated felines produced neutralizing antibody titers against all three variants.
The study showed neutralizing antibody titers against B.1.1.7 were not significantly impacted while neutralizing antibody titers against P1 and B.1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants.
The company believes these expected reductions in viral neutralization titers against two variants are unlikely to lead to a significant decrease in the effectiveness of the vaccine candidate against these variants in domestic felines.
It plans to initiate a SARS-CoV-2 challenge trial with mink in August 2021.
Price Action: APDN shares are up 1.98% at $5.92 during the market session on the last check Monday.